Cannabis Law Report

JULY 6, 2021

Drug Enforcement Agency’s approach, the DEA has notified marijuana grower applicants that they soon will be able to register as authorized entities to produce marijuana for research purposes. Prior to this announcement, there was only one DEA-approved supplier of cannabis for research purposes in the entire country.

DEA 105

DEA Research and Development Marijuana Epilepsy 105

CannaMD

SEPTEMBER 15, 2020

Patients suffering from cancer, epilepsy, chronic seizures, or muscle spasms could use low-THC cannabis products recommended by a licensed doctor. SHORT ANSWER: Full-time and seasonal Florida residents who suffer from an eligible medical condition. Regular cannabis does not have to meet the same requirements. Crohn’s Disease.

Law 126

Law Marijuana Patients Treatment 126

Cannabis Law Report

JULY 12, 2019

This differs sharply from the conventional course of cannabis medicine, which is to use whole, clean plant extracts to treat epilepsy and to gradually discontinue use of conventional pharmaceuticals. An Israeli study of cannabis versus epilepsy, however, used natural extracts with a ratio of 20:1 CBD:THC. References. 1Alexandra L.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Cannabis Law Report

SEPTEMBER 23, 2019

The AAFP advocates for robust regulation regarding labeling and child-proof packaging of all marijuana and cannabinoid products. 2,5,25 Improved sleep was also considered a secondary outcome when evaluating other conditions (chronic pain, multiple sclerosis) with various cannabinoids.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40